Russia Antacids Market Overview, 2031

Key Insights

• According to the research report, "Russia Antacids Market Outlook, 2031," published by Bonafide Research, the Russia Antacids Market is anticipated to grow at more than 3.77% CAGR from 2026 to 2031.
• Historically dominated by Western European and international pharmaceutical multinationals, the Russian antacid landscape is undergoing a major structural transformation driven by domestic import substitution. Local Russian pharmaceutical manufacturers are aggressively launching bioequivalent OTC formulations and combined adsorbents to fill supply chain gaps. Domestically produced antacid volume has expanded exponentially, with Russian brand sales growing over 78% in physical unit volume in early performance tracking. Domestic brands have successfully expanded their footprint from capturing just 3.2% of total unit sales in 2022 to expanding rapidly across retail pharmacy chains.
• Self-medication for gastrointestinal discomfort remains exceptionally high in Russia, driven by dietary habits, widespread availability of OTC remedies, and stress-related GI conditions. Retail market tracking from RNC Pharma indicates that annual antacid sales in Russia reached 24 million individual packages, generating 10.6 billion rubles in total retail revenue.
• Russian clinicians and consumers show a unique preference for combined anti-acid and cytoprotective/adsorbent therapies compared to standard Western markets. Liquid gel suspensions and oral pastes containing aluminum phosphate or magnesium-aluminum silicates paired with simethicone (anti-gas) dominate consumer choices. These formulations provide immediate acid neutralization alongside gastrointestinal mucosal protection, treating both upper GI heartburn and lower GI bloating simultaneously.

Market Outlook

• Following regulatory changes permitting full online ordering and home delivery of OTC medicines across Russia, digital pharmacy platforms (such as Apteka.ru and Eapteka) are becoming primary growth engines for antacid distribution, shifting consumer purchasing away from traditional brick-and-mortar retail outlets. Manufacturers are shifting production away from traditional large glass suspension bottles toward convenient single-dose foil sachets and chewable blister packs to meet consumer demand for on-the-go acid relief outside the home.
• Market standards and healthcare guidelines are shaped by professional bodies such as the Russian Gastroenterological Association (RGA) and the Association of International Pharmaceutical Manufacturers (AIPM), while the market is supplied by leading domestic and international companies including Renewal (PFC Renewal), Valenta Pharm, ABBA Rus, Sanofi, Teva Pharmaceutical Industries, and Bayer Healthcare.

Market Dynamics

Driver: Increasing prevalence of gastrointestinal disorders and self-medication
A key driver of the Russian antacids market is the growing need for accessible treatment of heartburn, acid reflux and other gastrointestinal symptoms, combined with a strong role for OTC/self-medication. Market research identifies increasing gastrointestinal disorders and acid reflux, together with greater consumer awareness of self-medication, as major growth drivers. This creates a relatively resilient demand base because antacids are typically purchased for rapid, episodic symptom relief rather than as long-term prescription therapies. Consumers can obtain products through retail and online pharmacies, making the category accessible across major population centers.
Challenge: Dependence on imported APIs and supply-chain/geopolitical risk
The major challenge for Russia's antacids industry is that domestic finished-product manufacturing does not eliminate dependence on imported pharmaceutical raw materials. Russia has expanded local production under its pharmaceutical import-substitution programs, but antacid manufacturers still rely substantially on internationally sourced APIs and pharmaceutical-grade ingredients such as calcium carbonate, magnesium hydroxide and aluminium hydroxide. Recent market research estimates that around 75-85% of API requirements for Russian antacid-tablet production are sourced overseas, primarily from India and China.
Trend: Shift toward combination, fast-dissolving and convenient formulations
The Russian market is gradually moving beyond traditional single-ingredient antacids toward combination formulations and more convenient dosage forms. Market research identifies growth in fast-dissolving tablets, flavored combinations and alginate-based/raft-forming products designed to address reflux symptoms in addition to simply neutralizing stomach acid. Convenience is becoming increasingly important because consumers are looking for products that can be used quickly and easily outside the home. This supports chewable tablets, liquid suspensions, sachets, effervescent formats and other portable presentations.

Procurement and Industry Impact

• Russia's domestic pharmaceutical industry has expanded its finished-dose manufacturing capabilities, but antacid production remains dependent on imported APIs. Estimates suggest 75–85% of antacid API requirements are sourced from India and China. Buyers should prioritize dual/multiple sourcing, strategic safety stock and long-term supplier agreements for calcium carbonate, magnesium hydroxide, aluminium hydroxide and other critical ingredients. Currency and logistics volatility can otherwise quickly increase COGS.
• Russia's pharmaceutical import-substitution strategy has encouraged local production of finished medicines. For antacid tablets, recent market analysis estimates domestic manufacturers supply approximately 65–75% of national unit demand, while imported finished products increasingly occupy premium segments. This favors Russian manufacturers and contract manufacturers with GMP-compliant tablet and liquid production capacity. It also creates procurement opportunities for domestically produced excipients, packaging and contract manufacturing, while reducing dependence on imported finished products.
• Strong consumer price sensitivity, private-label competition and higher input costs are putting pressure on manufacturers' margins. At the same time, Russia's antacid market is developing across retail and online pharmacies, increasing price transparency and making consumers more willing to compare brands and formulations. Procurement teams are likely to emphasize competitive bidding, local sourcing, packaging optimization and supplier consolidation, while product teams focus on higher-value combination/alginate formulations.

Segment Analysis

Russia Antacids Market By Drug Class
• Acid neutralizers remain an important part of gastrointestinal self-care in Russia because they provide direct, short-term relief by neutralizing gastric acid. Their role is particularly strong for episodic heartburn and acid-related discomfort, where consumers may prefer a rapidly acting product rather than a prolonged acid-suppression regimen. In the Russian MEGRE population study, 88% of respondents who used treatment to stop heartburn reported taking antacids, demonstrating their strong historical position in symptom-led self-treatment.
• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-control position because they reduce gastric acid secretion rather than neutralizing acid already present in the stomach. Their importance has increased in Russia as GERD treatment has become more closely aligned with evidence-based acid suppression. A multicenter Russian study covering 6,132 patients in eight cities found that 59.96% of patients with GERD used PPIs for heartburn relief, illustrating the strong clinical role of this class.
• H2 antagonists provide another acid-suppression mechanism by blocking histamine H2 receptors and reducing gastric acid secretion. Their position is more limited than that of PPIs in contemporary Russian GERD treatment, but they remain relevant for selected patients seeking acid reduction. In the same Russian multicenter study, 11.42% of patients reported using H2-histamine receptor blockers for heartburn relief, considerably below antacids and PPIs.
• Pro-motility agents represent a specialized gastrointestinal-treatment segment because their principal function is to influence gastrointestinal movement rather than neutralize gastric acid. They can be relevant when reflux symptoms are associated with impaired gastric emptying or gastrointestinal motility disturbances. Consequently, their use is more clinically directed and less dependent on spontaneous consumer self-medication than conventional Russian antacid products.
• Combination formulations are relevant because Russian consumers with reflux may experience several symptoms simultaneously, including heartburn, regurgitation, bloating and gas. Products combining antacids with alginates or anti-gas ingredients can provide broader symptom management. The Russian multicenter study found that 18.41% of patients used alginates for heartburn relief, supporting the importance of reflux-barrier approaches alongside conventional acid neutralization.

Russia Antacids Market By Dosage Form
• Tablets and chewables are particularly suitable for Russia's symptom-driven self-medication environment because they provide portable, unit-based dosing and can be taken without measuring equipment. Chewable formats are convenient after meals or while travelling and can be positioned around rapid relief. Their straightforward administration also supports pharmacy-based recommendation for consumers seeking treatment for occasional heartburn.
• Liquid suspensions provide an alternative for consumers who prefer liquid administration or have difficulty swallowing tablets. They also provide manufacturers with greater flexibility to combine multiple antacid ingredients within one formulation. Uniform suspension, accurate dosing, flavour and stability are important product characteristics because they directly influence consumer acceptance.
• Powders offer a non-tablet administration format and can be formulated for rapid dispersion after mixing. They may appeal to consumers looking for alternative dosage forms, although preparation requirements can reduce convenience compared with ready-to-use liquids or chewables. Moisture-resistant packaging and clear dosage instructions are therefore important for this segment.
• Gels and syrups emphasize smooth administration and can be particularly suitable for products combining acid neutralization with reflux-barrier mechanisms. Gel-forming alginate formulations can create a physical barrier that limits the movement of gastric contents toward the oesophagus. The reported use of alginates by 18.41% of GERD patients in a Russian multicenter study demonstrates the relevance of this mechanism in the country's treatment environment.
• Gummies and other formats represent a newer consumer-oriented opportunity within gastrointestinal self-care. Gummies can provide portability and a familiar administration experience, although achieving adequate active-ingredient delivery while maintaining acceptable taste and texture can be technically challenging. Effervescent and rapidly dispersible preparations can offer additional differentiation through convenience and perceived speed of action.

Russia Antacids Market By Indication
• Gastroesophageal Reflux Disease (GERD) is a major indication supporting Russia's broader acid-control market. A 2024 meta-analysis of 6 studies involving 34,192 subjects estimated overall GERD prevalence at 25.605%, indicating that approximately one in four people in the analyzed Russian populations met the study's GERD definition of heartburn and/or regurgitation at least weekly. This substantial symptom burden supports demand for both rapid-relief antacids and longer-acting acid-suppressive therapies.
• Heartburn is particularly important because Russian consumers have historically demonstrated a strong tendency toward self-treatment. The MEGRE study surveyed 7,812 adults across six Russian cities and found heartburn in 47.5% of respondents, including frequent heartburn in 9%. Among those treating heartburn, antacids were used by 88%, highlighting the strong association between this symptom and antacid self-care.
• Peptic ulcer represents a more clinically managed indication than occasional heartburn. Acid suppression through PPIs can support ulcer healing, while treatment may also require addressing an underlying cause such as H. pylori infection or medication-related mucosal damage. Conventional antacids are therefore better positioned as symptomatic-relief products rather than replacements for disease-directed ulcer therapy.
• Others include dyspepsia, acid indigestion, epigastric discomfort, sour stomach and overlapping upper-GI symptoms. The Russian MEGRE study found that frequent GERD symptoms were associated with dyspepsia in 19.8% of respondents, as well as frequent belching, nausea and other gastrointestinal complaints. This overlap creates opportunities for multi-symptom products rather than products positioned exclusively around acid neutralization.

Russia Antacids Market By Distribution Channel
• Retail pharmacies remain the principal environment for consumer access to non-prescription gastrointestinal medicines. Pharmacy-based purchasing is especially important because consumers can seek advice when deciding between conventional antacids, alginates, H2 antagonists and PPIs. The high level of self-treatment observed in Russian GERD studies reinforces the importance of accessible pharmacy channels.
• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, peptic ulcers, severe reflux complications and other gastrointestinal conditions. Demand through this channel is therefore more closely connected to physician diagnosis, hospital treatment protocols and prescription acid-suppression therapies than to spontaneous OTC purchases.
• Online pharmacies / E-commerce have a formally regulated role in Russia. Roszdravnadzor states that licensed pharmacy organizations with the appropriate authorization may conduct distance retail sales of non-prescription medicines. Prescription medicines, narcotic and psychotropic medicines and certain high-alcohol medicines are excluded from this general distance-sales framework.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce